A phase Ib study of miransertib (ARQ 092) in combination with anastrozole in patients with PIK3CA or AKT1-mutant ER+ endometrial or ovarian cancer Meeting Abstract

  

Authors:	Hyman, D.; Bonafede, M.; O'Cearbhaill, R.; Grisham, R.; Zamarin, D.; Tew, W.; Aghajanian, C.; Cadoo, K.; Friedman, C.; Savage, R. E.; Chai, F.; Schwartz, B.; Makker, V.
Abstract Title:	A phase Ib study of miransertib (ARQ 092) in combination with anastrozole in patients with PIK3CA or AKT1-mutant ER+ endometrial or ovarian cancer
Meeting Title:	109th Annual Meeting of the American Association for Cancer Research (AACR)
Journal Title:	Cancer Research
Volume:	78
Issue:	13 Suppl.
Meeting Dates:	2018 Apr 14-18
Meeting Location:	Chicago, IL
ISSN:	0008-5472
Publisher:	American Association for Cancer Research
Date Published:	2018-07-01
Language:	English
ACCESSION:	WOS:000468818900033
DOI:	10.1158/1538-7445.Am2018-ct035
PROVIDER:	wos
Notes:	Meeting Abstract: CT035 -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/148124